ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), and Freenome, a biotechnology company that has pioneered the most comprehensive multiomics platform for early cancer […]
GlaxoSmithKline (GSK) has announced its experimental drug belantamab mafodotin (GSK2857916) has met its primary endpoint in the DREAMM-2 trial of patients with relapsed and refractory multiple myeloma. The primary objective of the DREAMM-2 study was […]
SMi Group reports: Principal Scientist from Sanofi R&D is set to present at SMi’s5th Annual Lyophilization2 Day Conference taking place in Boston on October 23– 24, 2019. This year’s conference will explore novel and developing […]
BeyondSpring, a global biopharmaceutical company focused on the development of innovative cancer therapies, announced the results of its head-to-head clinical trial for Study BPI-2358-105, accepted as an abstract titled, “Quality of Life (QoL) in Advanced […]
AstraZeneca and MSD said that Lynparza (olaparib) in combination with standard-of-care (SoC) bevacizumab succeeded in a phase 3 trial in advanced ovarian cancer by meeting the primary endpoint. The late-stage study called PAOLA-1 evaluated Lynparza […]